Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Myelodysplastic Syndrome (MDS)
NCT00022048Phase 2Completed
- Sponsor
- Stanford University
- Start
- Aug 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Stanford University. Started Aug 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00022048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022048.